Exenatide.

Exenatide. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Exenatide. Abstract Text:

A Barnett,A Barnett,A Barnett,

Exenatide is the first in a new class of compounds, which possess similar activity to the naturally-occurring hormone glucagon-like peptide-1 (GLP-1). It mirrors many of the effects of GLP-1, improving glycaemic control through a combination of mechanisms, which include glucose-dependent stimulation of insulin secretion, suppression of glucagon secretion, slowing of gastric emptying and reduced appetite. Phase III clinical trials showed exenatide therapy for 30 weeks significantly reduced glycated haemoglobin, and fasting and postprandial plasma glucose compared with baseline when added to metformin and sulfonylureas or a combination of the two, with an average weight loss of approximately 2 kg. Exenatide can also be used in combination with thiazolidinediones and may be an alternative to insulin in patients requiring additional therapy. In patients with established Type 2 diabetes, control of both glycaemia and body weight are important to minimise the risk of future diabetes complications. Open-label extensions from these pivotal trials demonstrate that patients treated with exenatide for < or = 3 years sustained the reductions in glycaemic control achieved at 30 weeks and had a progressive reduction in body weight. Exenatide is generally well tolerated; nausea is the most commonly reported side effect, but can be significantly reduced when a target dose of exenatide is achieved in patients with gradual dose titration. Hypoglycaemia has been encountered in clinical trials of exenatide, especially on initiation of therapy with sulfonylureas (not with metformin). Exenatide may enable patients with Type 2 diabetes to improve glycaemic control and reduce or eliminate the risk of hypoglycaemia and weight gain.

Exenatide. Publishing Authors By Initials

A Barnett,A Barnett,A Barnett,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Exenatide. Journal Published:

PUBLICATION TYPE: Review

Journal: Expert opinion on pharmacotherapy

VOLUME: 8

Page Numbers: 2593-608

Journal Abbreviation:

ISSN: 1744-7666

DAY: 12

MONTH: Oct

YEAR: 2007

Exenatide. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100897346

Exenatide. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Exenatide. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Exenatide.

AFFILIATION: Birmingham Heartlands Hospital, Undergraduate Centre, Bordesley Green East, Birmingham, B9 5SS, UK. anthony.barnett@heartofengland.nhs.uk

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Expert Opin Pharmacother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Exenatide Related Publications

• 3,4-dichloropropionaniline suppresses normal macrophage function.
• A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules.
• A history of research on yeasts 10: foundations of yeast genetics.
• A proposed preoperative grading scheme to assess risk for surgical resection of primary and secondary intraaxial supratentorial brain tumors.
• Alteplase for the treatment of acute ischaemic stroke: NICE technology appraisal guidance.
• Behavioral economic approaches to reduce college student drinking.
• Broadening our view of protective antibody responses against HIV.
• Calponin is expressed by subpopulations of connective tissue cells but not olfactory ensheathing cells in the neonatal olfactory mucosa.
• Can mifepristone medication abortion be successfully integrated into medical practices that do not offer surgical abortion?
• Chemical vasectomy of domestic dogs in the Galapagos islands.
• Coronary vessel development is dependent on the type III transforming growth factor beta receptor.
• Electrode placement during stimulus evoked electromyographic monitoring of iliosacral screw insertion: a finite element model.
• Exenatide.
• Further evaluation of higher potency vaccines for early protection of cattle against FMDV direct contact challenge.
• Glucose tolerance testing for all?
• Long-term neurite orientation on astrocyte monolayers aligned by microtopography.
• Method of atrioventricular programming in atrial flutter in patients with biventricular pacemaker.
• Mutation in HSF4 associated with early but not late-onset hereditary cataract in the Boston Terrier.
• Online hysterectomy support: characteristics of Website experiences.
• Potential role of oral DPP-4 inhibitors in the ADA/EASD consensus statement algorithm for achieving and maintaining tight glycaemic control in type 2 diabetes: recommendations for oral antidiabetic agents.
• Predictors of alcohol use during the first year of college: implications for prevention.
• Review of Russian language studies on radionuclide behaviour in agricultural animals: part 2. Transfer to milk.
• Silicone augmentation of the lip.
• Surface proteins of gram-positive bacteria and how they get there.
• The Activity Inventory: an adaptive visual function questionnaire.
• The transfer of different forms of (35)S to goat milk.
• Toward the next generation of research into small area effects on health: a synthesis of multilevel investigations published since July 1998.
• Tris(2,2'-bipyridyl)ruthenium(II) chemiluminescence.
• Unusual presentation of myelopathy in a previously healthy man.
• Who should be considered at risk for maltreating their children?